Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study. Further, Glenmark has announced…
API major, Lasa Supergenerics Ltd in collaboration with Institute of Chemical Technology (ICT) recently announced commencement for Development of antiviral Compound Favipiravir as Covid-19 Treatment. Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said Health and safety of our countrymen is of pristine importance and to safeguard them from deadly corona we…